Description:Fruquintinib is a small molecule drug primarily used in the treatment of certain types of cancer, particularly colorectal cancer. It functions as a selective inhibitor of vascular endothelial growth factor receptors (VEGFR), which play a crucial role in tumor angiogenesis—the process by which tumors develop their own blood supply. By inhibiting these receptors, Fruquintinib effectively restricts tumor growth and metastasis. The compound is characterized by its oral bioavailability, allowing for convenient administration. Its chemical structure includes specific functional groups that contribute to its activity and selectivity. Fruquintinib has undergone various clinical trials to evaluate its efficacy and safety profile, demonstrating promising results in improving patient outcomes. As with many targeted therapies, potential side effects may include hypertension, fatigue, and gastrointestinal disturbances, necessitating careful monitoring during treatment. Overall, Fruquintinib represents a significant advancement in targeted cancer therapy, offering a novel approach to managing malignancies through the inhibition of angiogenic pathways.
We use cookies to enhance your visit. We do not include advertising.
Please see our Cookies Policy for more details or adjust your preferences in "Settings".
This is the advanced settings system for our own and third-party cookies. Here you can modify parameters that will directly affect your browsing experience on this website. If you wish you may check the list of Cookie types.
Please note that disabling cookies can cause failures in the normal operation of the web.
![6-[(6,7-Dimethoxy-4-quinazolinyl)oxy]-N,2-dimethyl-3-benzofurancarboxamide](https://static.cymitquimica.com/products/IN/thumb/DA003ATK.jpg)
